Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones gaining around 200 points. Here is the list of some big stocks recording gains in the previous session.
This Analyst Is Bullish On Evolent Health’s Recent Deal, Calls ‘Highly Strategic Acquisition’
Thursday after close, Evolent Health Inc (NYSE:EVH) agreed to acquire Magellan Specialty Health, the specialty benefit management organization owned by Centene…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Why PaxMedica Shares Are Trading Higher By Over 53%? Here Are 47 Stocks Moving In Friday’s Mid-Day Session
Gainers
PaxMedica, Inc. (NASDAQ: PXMD) gained 53.5% to $2.38 after the company announced an equity investment agreement for up to $20 million with Lincoln Park Capital.
Cowen & Co. Maintains Outperform on Evolent Health, Raises Price Target to $57
Cowen & Co. analyst Charles Ryhee maintains Evolent Health (NYSE:EVH) with a Outperform and raises the price target from $52 to $57.
Centene Agrees To Divest Magellan Specialty Health To Evolent Health
Evolent Health Inc (NYSE:EVH) has agreed to acquire NIA (also known as Magellan Specialty Health), the specialty benefit management organization owned by Centene…
Evolent Health Announces Acquisition Of Specialty Asset Nia And Strategic Partnership With Centene
Accelerates Evolent Health's Value-Based Specialty Care Market Leadership
Transaction Anticipated to be Immediately Accretive to Adjusted EBITDA Margins and Cash Flow
Highly Complementary Business Expected to
What 7 Analyst Ratings Have To Say About Evolent Health
Within the last quarter, Evolent Health (NYSE:EVH) has observed the following analyst ratings:
Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $48
Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $55 to $48.
BTIG Maintains Buy on Evolent Health, Lowers Price Target to $45
BTIG analyst David Larsen maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $55 to $45.